Healthcare
We focus on high-potential startups in biotech and pharmaceuticals, med-tech, and digital health care industries, along with broader biomedical and healthcare service sectors.
Portfolio Companies
Discover the companies in which we are investing under this strategy
COMPANY
HEADQUARTER
YEAR
PRODUCT
HEADQUARTER
Taiwan
YEAR
2018
PRODUCT
Contract development and manufacturing (CDMO)
EirGenix, a spin-off of Development Center for Biotechnology (DCB), undertook two cGMP pilot plants and outstanding DCB’s technicians. The company established two business units: one is contract development and manufacturing operation unit where EirGenix helps clients produce their biologics; the other is the product development operation unit where they hope to fully apply their team's experience and knowledge on biologics from biosimilars, and biobetters to new drugs.
HEADQUARTER
Taiwan
YEAR
2016
PRODUCT
Cancer genomic testing & profiling for cancer patients
ACT Genomics is a provider of precision therapeutic cancer evaluation services based on integrated genomics and bioinformatics analysis. Developed on its state-of-the-art next generation sequencing (NGS) platform, ACT Genomics offers a variety of innovative and advanced genomic diagnostic assays, such as treatment response prediction for immunotherapy, and liquid biopsy testing for monitoring drug resistance.
HEADQUARTER
Taiwan
YEAR
2016
PRODUCT
Specialty pharmaceuticals
Handa Pharmaceuticals is a specialty pharmaceutical company with a proven track record of developing controlled-release prescription drugs that are difficult to formulate. Handa focuses on high value, high barrier oral abbreviated new drug application (ANDA) products and develops 505(b)(2) New Drug Applications (NDA) products utilizing dosage form/formulation expertise as well.
HEADQUARTER
Taiwan
YEAR
2014
PRODUCT
New drug
Foresee Pharmaceuticals is a clinical-stage pharmaceutical company. Through its proprietary drug delivery technology, it has successfully developed and commercialized Camcevi, a long-acting injection drug for prostatic cancer. Meanwhile, it continues to develop first-in-class NCE in disease areas with highly unmet medical needs.
HEADQUARTER
USA
YEAR
2018
PRODUCT
Innovative pharmaceuticals and orphan drugs
LifeMax is a clinical stage biotech company focused on developing first-in-class or best-in-class therapeutics for orphan diseases or diseases with significant unmet medical needs.
HEADQUARTER
Hong Kong
YEAR
2018
PRODUCT
ADC drugs and innovative oncology therapies
TOT Biopharm is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies. The company has established three integrated technology platforms, including: The Therapeutic Monoclonal Antibody and Antibody Drugs Conjugates (ADC) Technology Platform, The Gene Engineering Based Therapeutics Technology Platform and The Innovative Drug Delivery Technology Platform.
HEADQUARTER
Taiwan
YEAR
2018
PRODUCT
Medical e-commerce platform
Med to Clinics is a subsidiary of Sharehope Medicine (8403 TT), known for its integration of the three largest medical information systems in Taiwan for the build-out of a B2B medical procurement cloud platform. The firm aims to cover 9,000 local clinics across Taiwan and provide brand new integrated procurement, inventory management and medical recommendation services to create win-win situations for clinics, pharmaceutical companies and patients.
HEADQUARTER
Taiwan
YEAR
2018
PRODUCT
long-acting release drug products for opioid use disorder, chronic pain, and major depressive disorder
Alar Pharmaceuticals Inc. (6785 TT) is a new 505(b)(2) drug development company focused on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorders, chronic pains, and major depressive disorders.
HEADQUARTER
Taiwan
YEAR
2016
PRODUCT
Stemchymal® allogeneic stem cells products
Steminent Biotherapeutics Inc. is a leading stem cell research and development company dedicated to the development of Stemchymal® allogeneic stem cells products. Its treatment of PolyQ Spinocerebellar Ataxia is a novel regenerative product in degenerative diseases.
HEADQUARTER
USA
YEAR
2018
PRODUCT
Immunotherapies for cancer with myeloid checkpoint inhibitors
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors that have the potential to transform current treatment approaches for blood cancers and solid tumors.
HEADQUARTER
Taiwan
YEAR
2020
PRODUCT
Leukocyte reduction filter
PuriBlood developed a unique technology for blood cell separation that is supported by a world-class research center – R&D center for membrane technology. PuriBlood is committed to improving the blood filtration process with innovative technology of "Zwitterionic-bias Surface Coating Technology (ZISC technology)”
HEADQUARTER
Taiwan
YEAR
2020
PRODUCT
New drug research and development
Pharmosa Biopharm Inc. develops existing drugs by exploiting innovative delivery formulations and medical devices, then bringing combined medicines to patients and healthcare providers. Its first new drug has entered phase III clinical trials and is expected to apply for FDA approval in two years.
HEADQUARTER
USA/Taiwan
YEAR
2021
PRODUCT
Targeted, allogeneic, off-the-shelf cell therapies
Acepodia is a clinical-stage biotechnology company developing targeted, allogeneic, off-the-shelf cell therapies to eradicate cancers of all types. Antibody-Cell Conjugation (ACC) platform, its novel technology links tumor-targeting antibodies to the surface proteins of its proprietary immune cells, oNK and NgdT cells. No complicated genetic engineering is required; therefore, the conjugation technology could be powerful, versatile, affordable, and safe. The Antibody-Conjugated Effector (ACE) cells significantly increase the avidity with cancer cells, which activates immune system and leads to effectively identifying and eliminating the targeted cancer cells robustly.
HEADQUARTER
Taiwan
YEAR
2021
PRODUCT
Proprietary drug formulation platform, ADC biosimilars
Formosa Pharmaceuticals, Inc., is a biotech company with an emphasis on ophthalmology, oncology, and anti-infectives. Its proprietary nanoparticle formulation technology (APNT) operates on the principle of API particle size reduction and subsequent stable formulation and is applicable towards innovative 505(b)(2) and novel drug prospects.
HEADQUARTER
Taiwan
YEAR
2021
PRODUCT
In vitro sperm diagnostic devices
Bonraybio is dedicated to developing vitro diagnostic devices with leading automated optical microscopy. It creates the product brand, LENSHOOKE & C-KUP, of automated high precision Sperm Analyzers to detect infertility.
HEADQUARTER
Wuhan
YEAR
2020
PRODUCT
Development of medicine for central nervous system disorders
XWPharma is a new drug development company with an emphasis on the clinical stage. The company capitalizes on its three new drug R&D platforms to design and develop new drugs for central nervous system disorders. It specializes in chemically engineering products that have already hit the market or have proven to be effective, turning them into the best-in-class in the same indication field.
HEADQUARTER
Suzhou
YEAR
2020
PRODUCT
Best-in-class and first-in-class new drug development
Founded in 2016, Sinovent is a clinical stage company addressing unmet medical needs and developing innovative best-in-class and first-in-class new drugs with global rights. It possesses 12 pipelines covering oncology, autoimmune, anti-infection and other therapeutic areas. From 2018 to 2020, it has been successively elected as the unicorn enterprise in Suzhou BioBay, and is preparing for the IPO on the SSE STAR Market.
HEADQUARTER
Zhejiang Huzhou
YEAR
2021
PRODUCT
Small-molecule treatments of non-small cell lung cancer, etc.
TYK Medicines, Inc. was established in 2017 and positioned as an international innovative anti-cancer biotechnology company in China with a global vision. Its candidates of drugs focus on treatments of EGFR+ non-small cell lung cancer, ER+HER2- breast cancer and other diseases. Based on deuterium technology and multi-target drug development platforms, it can effectively derive innovative molecules with clinically validated pathways.
HEADQUARTER
Shanghai
YEAR
2021
PRODUCT
AKT inhibitors for ovarian, prostate and other cancers
Laekna was founded in 2016 and headquartered in Zhangjiang, Shanghai with R&D and operations in the US and China. Laekna develops new targeted therapies to treat cancers and other diseases. It has collaborated with Novartis AG of Switzerland, obtaining global rights for 3 small-molecule tumor treatment candidates. Laekna continues their in-house R&D of new drugs and has advanced 3 drugs’ studies into Phase I/II clinical trials.
Value Creation
Our goal is to create value that will contribute to the growth of enterprises, investors and the whole community.
International Cooperation Opportunities
We act as a long-term strategic partner for portfolio companies, introducing international cooperation opportunities.
Business Value Maximization
We help prepare a concrete IPO plan or conduct M&A to maximize business value.
Expanding Chinese Medical Market
We implement local and global cutting-edge biomedical products and technology to address medical needs in the Chinese community.
NEXT
Buyout
We seek to seize premium returns in Greater China’s mid-market buyout segment, where generational transitions and market transformations lead to attractive buyout opportunities.